Onyema Ogbuagu
MBBCh, FACP, FIDSA
Associate Professor of Medicine (AIDS)
Research & Publications
Biography
News
Extensive Research Description
My clinical, educational and research interests revolve around improving the care and health outcomes of individuals living with or at risk for HIV/AIDS in domestic and international settings. Since 2011, I have been a member of the Yale AIDS Clinical Trials Program, and Director of the Program (since May 2017) and have been a principal and or co-investigator on numerous pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds (HIV). Most recently, given the alarming rate of new infections among men who have sex with men (MSM), I have added HIV prevention trials to my clinical trials activities. I am currently a co-principal investigator on a Yale CIRA funded project, which has supported the formation of a cohort of men who have sex with men, who are at high risk for HIV and are engaged in HIV PrEP services in order to study the impact of substance use on retention in care and adherence to PrEP.
Internationally, as a visiting professor to the National University of Rwanda since 2012, I have and continue to mentor medical residents and junior faculty, conducting meaningful clinical research projects that are locally relevant and addressing important infectious diseases-related problems (particularly HIV/AIDS and antimicrobial resistance). Similarly, in Liberia, as the Program Director of Yale’s Office of Global Health’s efforts to support Internal Medicine residency training, we have received funding (World Bank and HRSA) to support strengthening clinical research capacity in Liberia.
Coauthors
Research Interests
Hepatitis C; HIV Infections; Coronavirus; Disk Diffusion Antimicrobial Tests; Health Care
Public Health Interests
Antibiotic Resistance; Global Health; HIV/AIDS; e-Health
Selected Publications
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. HIV 2021, 8:e397-e407.
- Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.Tuan JJ, Zapata H, Critch-Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. HIV Medicine 2021.
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group.. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021, 385:239-250.
- A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?Tuan J, Spichler-Moffarah A, Ogbuagu O. A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding? BMJ Case Reports 2021, 14.
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020, 383:2603-2615.
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020, 324:1048-1057.
- Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers.Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham CO, Ogbuagu O, Patel VV, Phillips KA, Tetrault JM, Shah M, Blackstock O. Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. Preventive Medicine Reports 2020, 17:101012.
- Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings.Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2019, 23:190-200.
- HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system.Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care 2018, 30:1282-1289.
- Dolutegravir/rilpivirine for the treatment of HIV-1 infection.Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS (Auckland, N.Z.) 2018, 10:215-224.
- Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda.Kambutse I, Igiraneza G, Ogbuagu O. Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PloS One 2018, 13:e0207650.
- Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study. Medicine 2018, 97:e13016.
- Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations.Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49:534-544.
- Steroid-exacerbated HIV-associated cutaneous Kaposi's sarcoma immune reconstitution inflammatory syndrome: 'Where a good intention turns bad'.Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi's sarcoma immune reconstitution inflammatory syndrome: 'Where a good intention turns bad'. International Journal Of STD & AIDS 2016, 27:1026-9.
- Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12:721-31.
- Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Ogbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review Of Anti-infective Therapy 2016, 14:1113-1126.
- Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDS.Sherbuk J, Saly D, Barakat L, Ogbuagu O. Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDS. BMJ Case Reports 2016, 2016.
- Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda.Carroll M, Rangaiahagari A, Musabeyezu E, Singer D, Ogbuagu O. Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda. The American Journal Of Tropical Medicine And Hygiene 2016, 95:1277-1283.
- CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients.Tiberio PJ, Ogbuagu OE. CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients. AIDS Reviews 2015, 17:202-11.
- Single-pill regimens for HIV-1 infection.Ogbuagu O, Ogbuagu A. Single-pill regimens for HIV-1 infection. The New England Journal Of Medicine 2014, 371:1844.
- Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa.Sopeyin A, Hornsey E, Okwor T, Alimi Y, Raji T, Mohammed A, Moges H, Onwuekwe EVC, Minja FJ, Gon G, Ogbuagu O, Ogunsola F, Paintsil E. Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa. BMJ Global Health 2020, 5.
- Race and ethnicity do not impact eligibility for remdesivir: A single-center experience.Pischel L, Walelo M, Benson J, Osborn R, Schrier R, Tuan J, Barakat L, Ogbuagu O. Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PloS One 2021, 16:e0250735.
- Late neurosyphilis and VZV meningoencephalitis coinfection.Carr K, Ogbuagu O. Late neurosyphilis and VZV meningoencephalitis coinfection. BMJ Case Reports 2021, 14.
- Correction: Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda.Kambutse I, Igiraneza G, Shenoi S, Ogbuagu O. Correction: Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PloS One 2019, 14:e0212933.
- The Changing Face of HIV Care: Expanding HIV Training in an Internal Medicine Residency Program.Barakat LA, Dunne DW, Tetrault JM, Soares S, Chia D, Ogbuagu OE, Moriarty JP, Huot SJ, Green ML. The Changing Face of HIV Care: Expanding HIV Training in an Internal Medicine Residency Program. Academic Medicine : Journal Of The Association Of American Medical Colleges 2018, 93:1673-1678.
- Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative.Marsh RH, Plyler C, Miller M, Klar R, Adeiza M, Wachekwa I, Koomson F, Garlo JL, Kruah K, Lake SC, Matte R, Cook R, Maweu D, Kerr L, Ogbuagu O, Talbert-Slagle K, Dahn B. Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative. Annals Of Global Health 2021, 87:101.
Clinical Trials
| Conditions | Study Title |
|---|---|
| HIV/AIDS | Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection |
| Diseases of the Nervous System; HIV/AIDS; Infectious Diseases; COVID-19 Inpatient; COVID-19 Outpatient | HIV Associated Reservoirs and Comorbidities (The HARC Plus Study) |
| COVID-19 Vaccine | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |